We’re back with another round of Innovation Institute’s Tech Tuesdays, where we showcase the most cutting-edge technologies from our impressive portfolio of impactful innovations ready for licensing or strategic partnering!
This week we feature a groundbreaking technique that may help improve the health of people dealing with prostate issues. The technology is led by Youko Ikeda, Anthony J. Kanai, and Irina V. Zabbarova, who are all part of the Department of Medicine.
SUMMARY:
In 2022, the United States witnessed over 220,000 newly diagnosed cases of prostate cancer.
Researchers from the University of Pittsburgh have demonstrated that a soluble guanylate cyclase activator has the potential to treat age related prostatic hyperplasia and prostate cancer.
Treatment options for the more severe patient cases can include surgery, radiotherapy, and androgen deprivation therapy. This approach can destroy most cancerous cells, but surviving cells can become senescent and resistant to treatment, increasing the risk of reoccurrence. The novel approach described here can target these senescent cells, inducing apoptosis with the potential to improve patient outcomes.
{{cta(’30ebda60-ab2e-4f86-a395-440de64888f9′)}}
Stay tuned for the upcoming Tech Tuesday announcements, as we dive into the details of Pitt innovations, highlighting their impact and potential applications.